Parallel EMA-FDA Pediatric Advice On The Cards For Companies
Executive Summary
The European Medicines Agency is working on plans to supplement its early advice pilot on pediatric development by providing joint advice with the US FDA and, in some cases, by arranging for a three-way dialogue with companies.
You may also be interested in...
Mixed Results For EMA's Early Pediatric Advice Pilot
The European Medicines Agency has accepted only four of the 15 applications received so far under its early interaction pilot, which offers free scientific advice to drug companies in an effort to stimulate pediatric development1,2.
Oncology Benefits Most From EMA-FDA Pediatrics 'Cluster' Informal Advice
FDA and EMA staffers talk monthly on topics related to pediatric uses, resulting in 15 non-binding joint commentaries.
Getting Companies To Discuss Their Pediatric Research Plans Early: EMA Pilot Finally Gets Off To A Start
Interest is finally to beginning to pick up in the European Medicines Agency's pilot project on offering early scientific advice to drug sponsors to support the development of pediatric medicines. The pilot had initially drawn a lukewarm response from pharmaceutical companies, who showed reluctance to discuss their pediatric research plans with the agency at an early stage.